<\/p>\n
\ud83d\udca1 Snabbt svar<\/strong><\/p>\n Etibo<\/strong> \u00e4r lapatinib 250 mg<\/strong>, en dual HER2\/EGFR tyrosine kinase inhibitor<\/strong> for advanced or metastatic HER2-positive breast cancer<\/strong>. Oral once-daily therapy combined with capecitabine or other regimens, usually after trastuzumab (Herceptin) failure. Significant side effects include diarrhoea, rash, and cardiotoxicity; requires close oncologist supervision and ECG monitoring.<\/p>\n<\/div>\n \ud83d\udce6 Varje best\u00e4llning omfattas av v\u00e5r Reshipment Assurance Policy<\/strong><\/a> \u2014 om din f\u00f6rs\u00e4ndelse inte anl\u00e4nder inom 20 arbetsdagar, skickar vi om den.<\/p>\n V\u00e5ra generiska l\u00e4kemedel kommer fr\u00e5n WHO-GMP-certifierade tillverkare och skickas v\u00e4rldsvidt i diskreta, enkla f\u00f6rpackningar \u2014 inget l\u00e4kemedelsnamn p\u00e5 f\u00f6rs\u00e4ndelsens utsida. Kortbetalningar hanteras via en reglerad betalningsprocessor (kontoutdrag visar en reglerad kortbetalningsprocessor \u2014 aldrig \u201cMedsBase\u201d eller n\u00e5got l\u00e4kemedelsnamn). Krypto och SEPA-bank\u00f6verf\u00f6ring accepteras ocks\u00e5. Varje best\u00e4llning backas upp av v\u00e5r Reshipment Assurance Policy.<\/p>\n Etibo is a branded generic of lapatinib<\/strong> 250 mg, a small-molecule tyrosine kinase inhibitor that targets HER2 (ErbB2)<\/strong> och EGFR (ErbB1)<\/strong>. Lapatinib blocks intracellular signaling downstream of these receptors, halting proliferation of HER2-positive cancer cells. Manufactured by Natco Pharma.<\/p>\n Kritiskt:<\/strong> Lapatinib is an oncology drug used only under specialist supervision. It is not a general women’s health product. Use strictly according to oncologist protocol \u2014 typically after trastuzumab resistance develops.<\/p>\n Mycket vanligt:<\/strong> diarrhoea (60\u201380%), rash (40\u201360%), nausea, vomiting, fatigue, hand-foot syndrome, palmar-plantar erythrodysesthesia (with capecitabine combo).<\/p>\n Betydande:<\/strong> hepatotoxicity<\/strong> (monitor LFTs), cardiotoxicity \/ reduced LVEF<\/strong> (5\u20136%), QT prolongation, interstitial lung disease (rare but serious).<\/p>\n Allvarligt:<\/strong> severe liver injury, heart failure, severe skin reactions (Stevens-Johnson), pulmonary toxicity.<\/p>\n Store at room temperature (15\u201330 \u00b0C), away from moisture. Keep in original packaging. Keep out of reach of children.<\/p>\n Advanced\/metastatic HER2-positive breast cancer, typically after trastuzumab (Herceptin) resistance. Not used for early-stage curative therapy.<\/p>\n Food increases lapatinib absorption 4\u20135\u00d7, making dosing unpredictable. Standard is consistent fasting \u2014 1 hour before or after food \u2014 at a fixed time each day.<\/p>\n Common, often grade 1\u20132; manageable with loperamide and hydration. Grade 3+ diarrhoea may require treatment interruption and dose reduction. Report early.<\/p>\n About 5\u20136% of patients have asymptomatic LVEF drops. ECG + echocardiogram at baseline and every 3 months. Usually reversible on dose adjustment or interruption.<\/p>\n Combination lapatinib + trastuzumab is used in specific protocols. Not routine without oncologist supervision.<\/p>\n Effective contraception required during treatment and for 1 week after (teratogenic). Men should use effective contraception during and 3 months after.<\/p>\n HER2+ breast cancer disproportionately affects women (though rarely men get HER2+ breast cancer). Categorisation reflects the population, not a strict clinical cluster.<\/p>\n For second-line HER2+ metastatic disease (after trastuzumab), lapatinib + capecitabine was standard for years. Newer options (T-DM1\/Kadcyla, T-DXd\/Enhertu, tucatinib) have since largely supplanted it in first-world oncology \u2014 lapatinib remains important where newer agents are unavailable.<\/p>\n \u2695\ufe0f Medicinsk ansvarsfriskrivning:<\/strong> Informationen \u00e4r av pedagogisk karakt\u00e4r och ers\u00e4tter inte medicinsk r\u00e5dgivning. Konsultera en l\u00e4kare innan du p\u00e5b\u00f6rjar, avslutar eller \u00e4ndrar n\u00e5gon medicinering, s\u00e4rskilt vid cancerbehandling, hormonella behandlingar och receptbelagda produkter.<\/p>\n<\/div>\n <\/p>\n Andra onkologiska l\u00e4kemedel som finns i lager tillsammans med denna produkt:<\/p>\n \u2705 Targets cancer cells Etibo contains Lapatinib.<\/p>","protected":false},"featured_media":58016,"comment_status":"open","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3141,3223,3502],"product_tag":[4402,4403],"class_list":{"0":"post-58015","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-category-overview","8":"product_cat-chronic-conditions","9":"product_cat-womens-health","10":"product_tag-etibo","11":"product_tag-lapatinib","13":"first","14":"instock","15":"shipping-taxable","16":"purchasable","17":"product-type-variable","18":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product\/58015","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/comments?post=58015"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media\/58016"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/media?parent=58015"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_brand?post=58015"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_cat?post=58015"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/sv\/wp-json\/wp\/v2\/product_tag?post=58015"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Varf\u00f6r best\u00e4lla fr\u00e5n MedsBase<\/h3>\n
What Is Etibo?<\/strong><\/h2>\n
Kliniska anv\u00e4ndningsomr\u00e5den<\/strong><\/h2>\n
\n
Hur man tar<\/strong><\/h2>\n
\n
Biverkningar<\/strong><\/h2>\n
Who Should Not Take Etibo<\/strong><\/h2>\n
\n
L\u00e4kemedelsinteraktioner<\/strong><\/h2>\n
\n
F\u00f6rvaring<\/strong><\/h2>\n
Vanliga fr\u00e5gor<\/h2>\n
When is lapatinib used?<\/h3>\n
Why take on empty stomach?<\/h3>\n
How bad is the diarrhoea?<\/h3>\n
Will lapatinib damage my heart?<\/h3>\n
Can I take lapatinib with trastuzumab?<\/h3>\n
What about fertility?<\/h3>\n
Why is this in the Women's Health category?<\/h3>\n
Is lapatinib still first-line?<\/h3>\n
Relaterade produkter f\u00f6r kvinnors h\u00e4lsa<\/h3>\n
\n
Relaterade alternativ<\/h3>\n
\n
\n\u2705 Inhibits tumor growth
\n\u2705 Treats breast cancer
\n\u2705 Blocks HER2 receptors
\n\u2705 F\u00f6rb\u00e4ttrar \u00f6verlevnadsgraden<\/p>\n